Cell Proliferation News and Research

RSS

Blocking mir-21 shows promise for slowing bladder cancer growth

Bladder cancer ranks among the ten most common types of cancer worldwide. The main treatment is bladder removal surgery, and despite advances in systemic therapies, recurrence is frequent in the most aggressive forms of the disease.

18 Nov 2025

Exploring m6A RNA modification as a therapeutic target in cardiovascular disorders

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs).

14 Nov 2025

Transforming colorectal cancer research with patient-derived xenograft models

Patient-derived xenograft (PDX) models are emerging as a transformative tool in colorectal cancer (CRC) research, offering unparalleled insights into tumor biology, drug resistance, and personalized treatment approaches.

14 Nov 2025

Exosomes identified as key mediators in obstructive sleep apnea and its comorbidities

Obstructive sleep apnea (OSA), a global public health issue marked by repeated upper airway collapse during sleep, is tied to diverse diseases-from cardiovascular conditions to cancer.

12 Nov 2025

Trojan horse strategy using cesium nanosalts shows powerful anti-cancer effects

Recently, a team led by Academician Hongjie Zhang, Researcher Shuyan Song, Associate Researcher Pengpeng Lei, and Dr. Ran An at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, developed an innovative strategy to construct a series of biodegradable cesium nanosalts.

4 Nov 2025

Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

30 Oct 2025

Two microbial metabolites compete to control the cells' protein building machinery

The microbiome-the trillions of bacteria, viruses, and fungi that live quietly in our body-plays a crucial role in shaping human health by providing a variety of micronutrients necessary for vital functions.

30 Oct 2025

Rapamycin shows promise in treating cold tumors with specific gene mutation

Immune checkpoint inhibitors (ICIs) emerged in the US about 15 years ago as an exciting class of cancer treatments that have achieved complete and durable remissions for thousands of people with end-stage metastatic cancers.

29 Oct 2025

Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

27 Oct 2025

New drug combination shows promise in treating colorectal cancer

Colorectal cancer is one of the most common tumors among people over the age of 50. Although it is known to develop from small lesions or polyps, its exact causes are unknown — only a few risk factors are known — and it is usually treated with surgery, chemotherapy and radiotherapy, or biological therapies.

22 Oct 2025

Researchers develop a novel approach to monitor CD8⁺ T cell activity over time

The ability of immune cells-particularly CD8+ T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies.

21 Oct 2025

Multidimensional regulation of stem cell fate by the cohesin complex

Conventional studies on stem cell fates are primarily focused on transcription factors, with the limited consideration for 3D genome architecture.

10 Oct 2025

Study reveals a new oncogenic role of NBL1 in ovarian cancer metastasis

Ovarian cancer (OC), one of the three most common gynecological malignancies, is characterized by low early detection rates and poor prognosis.

23 Sep 2025

Targeting miR-378 could offer a dual-action strategy against osteoporosis

Osteoporosis is a degenerative disease characterized by decreased bone mass and damage to bone microarchitecture, as well as increased bone fragility.

23 Sep 2025

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.

17 Sep 2025

Cell Proliferation News and Research

Blocking mir-21 shows promise for slowing bladder cancer growth

Exploring m6A RNA modification as a therapeutic target in cardiovascular disorders

Transforming colorectal cancer research with patient-derived xenograft models

Exosomes identified as key mediators in obstructive sleep apnea and its comorbidities

Trojan horse strategy using cesium nanosalts shows powerful anti-cancer effects

Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway

Two microbial metabolites compete to control the cells' protein building machinery

Rapamycin shows promise in treating cold tumors with specific gene mutation

Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug

New drug combination shows promise in treating colorectal cancer

Researchers develop a novel approach to monitor CD8⁺ T cell activity over time

Multidimensional regulation of stem cell fate by the cohesin complex

Study reveals a new oncogenic role of NBL1 in ovarian cancer metastasis

Targeting miR-378 could offer a dual-action strategy against osteoporosis

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

Novel biotechnical vector integrates viral and synthetic features for targeted cancer therapy

Study identifies C1orf122 as prognostic marker in liver cancer

RAB26 identified as a critical regulator of prostate cancer aggressiveness

Cancer cells found to use ketones as alternate fuel for growth

Targeting metabolic reprogramming to overcome immune suppression in head and neck cancer

Event Guide: 3rd Annual TRP Supply Chain & Manufacturing Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News